Genzyme, a Sanofi company, announced today that the Saskatchewan Drug Program has included Aubagio (teriflunomide) 14 mg on the provincial drug formulary as a first-line oral agent for people in the province living with relapsing remitting multiple sclerosis (RRMS). 

Aubagio is used as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.

"It's exciting news that Saskatchewanians with relapsing remitting multiple sclerosis will now have access to a new oral choice for first-line therapy to help reduce their disease activity. This expansion of our available therapeutic options will directly benefit the many people in the province with MS. I applaud the Saskatchewan government for leading the way with this approval," says Dr. Andrew Kirk, Professor and Head of Neurology at the University of Saskatchewan.

For more details, go to: http://www.newswire.ca/en/story/1437867/saskatchewan-to-fund-treatment-with-aubagio-for-relapsing-remitting-multiple-sclerosis